HPV E6/E7 mRNA与液基薄层细胞学联合检测在宫颈癌风险预测中的应用及探讨  

Application and Exploration of Combined Detection of HPV E6/E7 mRNA and Thinprep Cytologic Test (TCT) in Predicting the Risk of Cervical Cancer

作　　者：张玉[1] 王欢 何朵 景彩萍[1] 刘王静 郝向云 强倩倩 李旭[1] 霍媛媛[1] 

机构地区：[1]延安市人民医院病理科,陕西 延安

出　　处：《临床医学进展》2024年第12期27-32,共6页Advances in Clinical Medicine

基　　金：延安市科技计划项目(SL2022SLSFGG-013)。

摘　　要：目的:探讨人乳头状瘤病毒(HPV) E6/E7 mRNA与液基薄层细胞学检查(TCT)联合检测在宫颈癌风险预测中的应用价值。方法:选取2023年1月至2024年6月于延安市人民医院行宫颈癌和癌前病变筛查的216例患者作为研究对象,对其资料进行回顾性分析,该部分患者均同时行HPV E6/E7 mRNA与液基薄层细胞学检测联合及组织病理学检查,分析HPV E6/E7 mRNA与液基薄层细胞学单独检测及两者联合检测宫颈癌的灵敏性、特异性、阳性预测值及阴性预测值。结果:216例患者中,HPV E6/E7mRNA与液基薄层细胞学单独检测的敏感性、特异性、阳性预测值、阴性预测值分别为78.41%、42.50%、85.71%、30.91%和71.59%、62.50%、89.36%、33.33%;HPV E6/E7 mRNA与液基薄层细胞学联合检测的敏感性、特异性、阳性预测值、阴性预测值为93.19%、65.00%、92.13%、68.42%,差异均有统计学意义(P Purpose: To explore the application value of HPV E6/E7 mRNA and Thinprep cytologic test (TCT) in predicting the risk of cervical cancer. Methods: 216 patients who underwent HPV E6/E7 mRNA and TCT at Yan’an People’s Hospital from January 2023 to June 2024 were selected as the study subjects. The data were retrospectively analyzed. All patients underwent HPV E6/E7 mRNA combined with TCT and histopathological examination. The sensitivity, specificity, positive predictive value, and negative predictive value of HPV E6/E7 mRNA and TCT detected separately and combinedly for cervical cancer were analyzed. Results: Among 216 patients, the sensitivity, specificity, positive predictive value, and negative predictive value of HPV E6/E7 mRNA and TCT detected separately were 78.41%, 42.50%, 85.71%, 30.91% and 71.59%, 62.50%, 89.36% and 33.33%;The sensitivity, specificity, positive predictive value, and negative predictive value of combined detection of HPV E6/E7 mRNA and TCT were 93.19%,65.00%, 92.13%, and 68.42%, with statistically significant differences (P < 0.05). Conclusion: The combined det

关 键 词：HPV E6/E7 mRNA 液基薄层细胞学检查 宫颈癌 

分 类 号：R73[医药卫生—肿瘤]